French Court Denies Roche Action Over Avastin In AMD
This article was originally published in Scrip
A judge at France's top administrative court, the Conseil d'Etat, has denied a request from Roche to suspend the government's decision to reimburse its anticancer, Avastin (bevacizumab), for the off-label indication of wet age-related macular degeneration (AMD).
You may also be interested in...
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
Russia’s new drug traceability system won’t now be implemented until July, but companies that are ready and able are being encouraged to put the system through its paces in order to flush out any glitches.